Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma
- PMID: 40328775
- PMCID: PMC12055983
- DOI: 10.1038/s41467-025-59298-w
Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma
Abstract
Advancements in chimeric antigen receptor (CAR) T-cell therapy for treating diffuse large B-cell lymphoma (DLBCL) have been limited by an incomplete understanding of CAR T-cell differentiation in patients. Here, we show via single-cell, multi-modal, and longitudinal analyses, that CD8+ CAR T cells from DLBCL patients successfully treated with axicabtagene ciloleucel undergo two distinct waves of clonal expansion in vivo. The first wave is dominated by an exhausted-like effector memory phenotype during peak expansion (day 8-14). The second wave is dominated by a terminal effector phenotype during the post-peak persistence period (day 21-28). Importantly, the two waves have distinct ontogeny from the infusion product and are biologically uncoupled. Precursors of the first wave exhibit more effector-like signatures, whereas precursors of the second wave exhibit more stem-like signatures. We demonstrate that CAR T-cell expansion and persistence are mediated by clonally, phenotypically, and ontogenically distinct CAR T-cell populations that serve complementary clinical purposes.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: P.A.R. reports Research Support/Funding: BMS, Kite Pharma, Inc./Gilead, MorphoSys, Calibr, Tessa Therapeutics, Fate Therapeutics, Xencor, and Novartis Pharmaceuticals Corporation. Speaker’s Bureau: Kite Pharma, Inc./Gilead; Consultancy on advisory boards: AbbVie, Novartis Pharmaceuticals Corporation, BMS, Janssen, BeiGene, Karyopharm Therapeutics Inc., Takeda Pharmaceutical Company, Kite Pharma, Inc./Gilead, Sana Biotechnology, Nektar Therapeutics, Nurix Therapeutics, Intellia Therapeutics, and Bayer. Honoraria: Novartis Pharmaceuticals Corporation. M.R.B. reports Membership on an Advisory Board or Consultancy for Kite/Gilead, Novartis, CRISPR Therapeutics, Autolus Therapeutics, BMS, Incyte, Sana Biotechnology, Iovance Biotherapeutics. He has served on a Speakers Bureau for BMS, Kite/Gilead, Agios, and Incyte. J.P.K. receives research support from Merck, Verastem, and iTeos; has served on a speaker’s bureau for Kite/Gilead; and has served on advisory boards for Verastem, Seattle Genetics, MorphoSys, and Karyopharm. The remaining authors declare no competing interests.
Figures






Update of
-
Two-Stage CD8+ CAR T-Cell Differentiation in Patients with Large B-Cell Lymphoma.bioRxiv [Preprint]. 2025 Mar 15:2025.03.05.641715. doi: 10.1101/2025.03.05.641715. bioRxiv. 2025. Update in: Nat Commun. 2025 May 6;16(1):4205. doi: 10.1038/s41467-025-59298-w. PMID: 40161759 Free PMC article. Updated. Preprint.
References
-
- Diffuse Large B-Cell Lymphoma - Cancer Stat Facts. https://seer.cancer.gov/statfacts/html/dlbcl.html
-
- Liu, Y. & Barta, S. K. Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am. J. Hematol.94, 604–616 (2019). - PubMed
-
- Longo, D. L., Sehn, L. H. & Salles, G. Diffuse large B-cell lymphoma. https://doi-org.proxy.uchicago.edu/10.1056/NEJMra2027612, 384, 842–858 (2021). - DOI - PMC - PubMed
-
- June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science359, 1361–1365 (2018). - PubMed
MeSH terms
Substances
Grants and funding
- T32 GM007281/GM/NIGMS NIH HHS/United States
- 5UL1TR002389-02/U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS)
- UL1 TR002389/TR/NCATS NIH HHS/United States
- DP2 AI144245/AI/NIAID NIH HHS/United States
- T32 CA009594/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources